22 Jan SmartCella
Ricardo Baptista, Ph.D., Chief Technology Officer
April 29 | 11:15am | Salone dei Cavalieri, Section 1
Stockholm, Sweden
(Private)
SmartCella is a Sweden-based biopharma company developing next-generation regenerative and molecular therapeutics supported by advanced targeted-delivery technology. At the core is the Extroducer®, a first-in-class endovascular infusion catheter designed to overcome limitations in accessing hard-to-reach tissues and organs. The Extroducer enables precise intraparenchymal administration of cells, genes, biologics, or small molecules through a controlled micro-needle that safely crosses the vessel wall while maintaining vascular integrity. This minimally invasive approach improves targeting accuracy, reduces systemic exposure, and may lower effective doses through localized delivery. By avoiding open surgery, it reduces patient burden, shortens recovery, and supports repeat or multi-site dosing with high reproducibility. Preclinical studies across multiple organs demonstrate localized biodistribution, favorable safety, and consistent procedural performance. This presentation outlines SmartCella’s vision, the engineering principles behind the Extroducer, and key translational data supporting its clinical advancement, positioning the technology as an enabling platform for precise targeted delivery.
